Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
48 Results Found
AHA Statement on Final 340B Administrative Dispute Resolution Process Rule From HHS
The Administration’s final rule for the 340B drug pricing program administrative dispute resolution (ADR) process is an important step in ensuring the integrity of the 340B program. The final rule contains several important process improvements, including a clear timeline for when ADR decisions must be made and an opportunity for reconsideration when parties are dissatisfied with the initial ADR decision.
AHA Statement on Final 340B Remedy
Following years of litigation and a unanimous Supreme Court win, the AHA is very pleased that 340B hospitals finally will be reimbursed in full for what HHS unlawfully withheld from them for five years.
AHA Statement on Proposed 340B Remedy
After more than five years of litigation and a unanimous Supreme Court victory, the AHA is extremely pleased that 340B hospitals will finally be paid back what they deserve so they can continue pro
AHA, 340B Health, Arkansas Hospital Association Urge Federal Appeals Court 340B Community Pharmacies to Uphold State Law Protecting
The American Hospital Association (AHA), 340B Health, and the Arkansas Hospital Association told the U.S. Court of Appeals for the Eighth Circuit that Arkansas’s 340B Drug Pricing Nondiscrimination Act does not conflict with federal law but rather supports Congress’s goal in enacting the 340B program.
Joint Statement From National Hospital Associations on PhRMA-Led Proposal to Restrict 340B Eligibility
Hospital and pharmacist advocates for safety-net health care and affordable prescription drugs are united in their firm opposition to a misguided effort by the drug industry and some community health centers that would restrict access to the 340B drug pricing program.
AHA Statement on Alliance to Save America's 340B Program
The AHA will continue to fight to protect the 340B program and the patients it benefits against unfounded attacks by big drug companies.
AHA Advertorial: 340B Drug Pricing Program Helps Advance Health for Patients and Communities
For 30 years, the 340B drug pricing program has helped eligible hospitals offer a wide range of important programs and services that benefit patients and advance health within their communities.
AHA Statement on District Court Decision in 340B Case
For more than five years, the Department of Health and Human Services has unlawfully withheld vital funding from 340B hospitals that helps them provide a range of important benefits to their patients and communities. We are disappointed that the district court elected to extend this delay by remanding this case back to the department to determine the appropriate remedy.
AHA Survey: Drug Companies Reduce Access to Care by Limiting 340B Community Pharmacies
The American Hospital Association (AHA) today released a new report showing how the unlawful actions of drug companies to limit 340B pricing with community and specialty pharmacies are having an adverse impact on access to care for patients and communities across the country.
AHA Statement on 2023 OPPS Final Rule
While the AHA is pleased that CMS will provide hospitals and health systems with an improved update to outpatient payments next year compared to the agency’s proposal in July, the increase is still insufficient given the extraordinary cost pressures hospitals face from labor, supplies, equipment, drugs and other expenses.